Practice-changing melanoma and skin cancer treatments come from clinical trials.
Melanoma and Skin Cancer Trials (MASC Trials) is Australia and New Zealand’s collaborative trials group specialising in investigator-initiated melanoma and skin cancer research. Working with leading researchers and institutions locally and around the globe, MASC Trials develops, conducts, and publishes research and clinical trials that improve how we diagnose and treat melanoma and skin cancer.
Clinical trials save lives - donate today
Melanoma and skin cancer do not discriminate. These cancers affect young and old, men and women, in big cities and in small towns.
Donate now and support our most promising researchers to find cures for melanoma and skin cancers, and give survivors long and healthy lives.
What We Do
MASC Trials brings together a powerful network of almost 2,000 professionals who represent the many disciplines critical to our work – oncologists, surgeons, radiation specialists, nurses, allied health professionals, health economists, statisticians, research scientists, clinical research associates, data managers, patient advocates and others.
With expert support from our Advisories and our trials staff, MASC Trials leads and designs research and clinical trial development, and provides project management for multicentre, national and international collaborations.
Active Trials Closed for Recruitment
An Australian-led trial is now gathering melanoma experts from around the world to contribute results from 3,000 patients to determine the optimal surgical excision margin for melanoma of the skin.
Leading Merkel cell carcinoma expert, Dr Wen Xu, recently presented two Australian clinical trials at the 2nd International Symposium of Merkel Cell Carcinoma in Seattle, USA.
The I-MAT clinical trial is giving patients with early-stage Merkel cell carcinoma an immunotherapy drug after their initial surgery and / or radiotherapy for the cancer to improve their cure rates.